Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates

2022 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. ;2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. ;2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2050-0068 ;EISSN: 2050-0068 ;DOI: 10.1002/cti2.1379 ;PMID: 35284072

Full text available